Lantern Pharma Statistics
Share Statistics
Lantern Pharma has 10.78M shares outstanding. The number of shares has increased by 0.4% in one year.
| Shares Outstanding | 10.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.04M |
| Failed to Deliver (FTD) Shares | 1.98K |
| FTD / Avg. Volume | 3.06% |
Short Selling Information
The latest short interest is 176.91K, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 176.91K |
| Short % of Shares Out | 1.64% |
| Short % of Float | 2.2% |
| Short Ratio (days to cover) | 4.74 |
Valuation Ratios
The PE ratio is -2.91 and the forward PE ratio is -1.77.
| PE Ratio | -2.91 |
| Forward PE | -1.77 |
| PS Ratio | 0 |
| Forward PS | 19.1 |
| PB Ratio | 1.13 |
| P/FCF Ratio | -3.23 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lantern Pharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.18, with a Debt / Equity ratio of 0.
| Current Ratio | 16.18 |
| Quick Ratio | 16.18 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.39% and return on capital (ROIC) is -43.45%.
| Return on Equity (ROE) | -0.39% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -43.45% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -760.07K |
| Employee Count | 21 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -12.02% in the last 52 weeks. The beta is 1.57, so Lantern Pharma 's price volatility has been higher than the market average.
| Beta | 1.57 |
| 52-Week Price Change | -12.02% |
| 50-Day Moving Average | 3.44 |
| 200-Day Moving Average | 4.5 |
| Relative Strength Index (RSI) | 48.36 |
| Average Volume (20 Days) | 64.66K |
Income Statement
| Revenue | n/a |
| Gross Profit | -174.84K |
| Operating Income | -17.88M |
| Net Income | -15.96M |
| EBITDA | -15.79M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.47 |
Balance Sheet
The company has 21.94M in cash and 234.47K in debt, giving a net cash position of 21.70M.
| Cash & Cash Equivalents | 21.94M |
| Total Debt | 234.47K |
| Net Cash | 21.70M |
| Retained Earnings | -55.24M |
| Total Assets | 30.29M |
| Working Capital | 26.32M |
Cash Flow
In the last 12 months, operating cash flow was -14.35M and capital expenditures -18.73K, giving a free cash flow of -14.37M.
| Operating Cash Flow | -14.35M |
| Capital Expenditures | -18.73K |
| Free Cash Flow | -14.37M |
| FCF Per Share | -1.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LTRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -42.73% |
| FCF Yield | -38.66% |
Analyst Forecast
Currently there are no analyst rating for LTRN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 2.04 |
| Piotroski F-Score | 3 |